Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q1 2022 · 10-Q
Revenue$497.63M$497.63M+0.9% vs Q1 2021 Net Income-$8.82M-$8.82MN/M vs Q1 2021 EPS Diluted-$0.01-$0.01N/M vs Q1 2021 Gross Profit$174,571,000−8.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flow$120,343,000−18.8% Free Cash Flowderived$109,550,000−19.7% Margins · derivedGross margin35.1%−3.8 pt vs Q1 2021
Operating margin4.7%−4.6 pt vs Q1 2021
Net margin-1.8%−4.4 pt vs Q1 2021
ended Mar 31, 2022 · filed May 6, 2022 · 36 d after period end